Evidence map›Paper›PMID 14567085›Full record

ReviewDer Internist2003

[Chronic obstructive lung disease].

C Vogelmeier

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

C VogelmeierKlinik für Innere Medizin, Klinikum der Philipps-Universität Marburg. Claus.Vogelmeier@med.uni-marburg.de
Philipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. Recently, international guidelines for diagnosis, prevention and therapy have been published. Now also a modified German version of these guidelines is available. The diagnosis and the severity of the disease is established on the basis of spirometric findings. All stages of COPD are treated with bronchodilators (beta 2-sympathomimetics and anticholinergics). In addition, in stage II and III theophylline and inhaled corticosteroids may be used. Systemic steroids should be restricted to acute exacerbations. For patients with advanced COPD long-term oxygen therapy and in selected cases surgical procedures may be indicated. Rehabilitation measures are of high value. Strategies for primary prevention and smoking cessation programs are extremely important. To get to the diagnosis of COPD as early as possible, all smokers with cough and phlegm should undergo spirometry.

Indexed as

Adrenal Cortex HormonesBronchodilator AgentsCause of DeathCross-Sectional StudiesDrug Therapy, CombinationHumansOxygen Inhalation TherapyPrognosisPulmonary Disease, Chronic ObstructiveRisk FactorsSmoking CessationAdrenal Cortex HormonesBronchodilator Agents

Identifiers

PMID14567085
OpenAlexW2434064047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.